Article
Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.
Addiction biology - 1 Jan 2013
Kranzler Henry R, Armeli Stephen, Covault Jonathan, Tennen Howard
Abstract excerpt
To evaluate the role of the functional Asn40Asp polymorphism in the mu-opioid receptor gene on drinking behavior and naltrexone's ability to attenuate drinking, we used a daily diary method in a 12-week, randomized clinical trial of naltrexone to reduce drinking. Participants (n = 158 problem drinkers) were assigned to receive either daily or targeted naltrexone 50 mg (n = 81) or matching placebo (n = 77)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.